Soleno Therapeutics (NASDAQ:SLNO – Free Report) had its price target increased by Cantor Fitzgerald from $67.00 to $123.00 in ...

Cantor Fitzgerald issued their FY2024 EPS estimates for shares of Intuitive Machines in a research report issued to clients ...

Cantor Fitzgerald predicts a short-term market rally but warns of bearish trends ahead. Learn more information here.

Crypto lending is back, and traditional financial firm Cantor Fitzgerald as well as crypto firms Blockstream and Xapo are in ...

Cantor Fitzgerald just dropped $2 billion into a new Bitcoin lending business. That move alone shoved the whole crypto ...

Tesla (NASDAQ:TSLA) attracted an upgrade from Cantor Fitzgerald on Wednesday after the firm visited the company's Gigafactory ...

Meeting to be held in San Francisco on March 31 hosted by Cantor Fitzgerald.Light Up your Portfolio with Spark:Easily identify stocks' risks ...

Stock analysts at Cantor Fitzgerald, the firm long led by now-U.S. Commerce Secretary Howard Lutnick, upgraded their rating ...

In a report released today, Andres Sheppard from Cantor Fitzgerald maintained a Buy rating on Ouster (OUST – Research Report), with a price target of $11.00. The company’s shares closed ...

Cantor Fitzgerald assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating.Cantor is bullish on the TSLP and IL-4R bispecific, which looks differentiated, and even early proof-of ...

Fintel reports that on March 19, 2025, Cantor Fitzgerald upgraded their outlook for Tesla (SNSE:TSLACL) from Neutral to Overweight. There are 5,232 funds or institutions reporting positions in Tesla.

On Monday, Cantor Fitzgerald reaffirmed its Overweight rating on Cartesian Therapeutics (NASDAQ:RNAC), currently trading at $15.80, with a steady price target of $22.00. The stock has experienced an ...